Considering that the toxicity caused by GSI in humans may not be well tolerated, it is of interest whether CXCR3 inhibitor is preferable to GSI in combination with TKI against FLT3/ITD + AML for safety concerns. The gene discussed is FLT3; the disease is acute myeloid leukemia.